Lisuride in parkinsonism.
We studied the actions of lisuride, a dopaminergic ergot derivative, in 20 parkinsonian patients. When the dose was increased gradually, most patients tolerated up to 5 mg daily. Clinical assessment and objective, computer-assisted evaluation revealed improvement in akinesia, rigidity and tremor. Adverse reactions were similar to those seen with levodopa and bromocriptine, but somnolence tended to occur more often with lisuride.
D000328:Adult; D000368:Aged; D001971:Bromocriptine / Q000627:therapeutic use; D004311:Double-Blind Method; D004873:Ergolines / Q000627:therapeutic use*; D006801:Humans; D008090:Lisuride / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009068:Movement; D010300:Parkinson Disease / Q000188:drug therapy*; D010919:Placebos; D011930:Reaction Time; D011985:Receptors, Serotonin / Q000187:drug effects; D012890:Sleep / Q000187:drug effects
D004873:Ergolines; D010919:Placebos; D011985:Receptors, Serotonin; D001971:Bromocriptine; D008090:Lisuride